DOPAMINE AGONISTS FOR THE THERAPY OF COCAINE ADDICTION

多巴胺激动剂治疗可卡因成瘾

• 批准号: 6379037
• 负责人: John L Neumeyer
• 金额: $ 39.18万
• 依托单位: BRAIN RESEARCH LABORATORIES, INC. (BRL)
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6379037
• 关键词: Macaca mulatta; Saimiri; adenylate cyclase; analog; behavior test; behavioral /social science research tag; benzazepines; cocaine; dopamine agonists; dopamine receptor; drug abuse chemotherapy; drug addiction antagonist; drug design /synthesis /production; drug screening /evaluation; laboratory rat; nonhuman therapy evaluation; pharmacokinetics; receptor binding; reinforcer; self medication; substance abuse related behavior

Evidence for dopamine D1 receptor involvement in the reinforcing and other behavioral effects of cocaine and other psychomotor stimulant drugs suggests that D1 mechanisms are rational targets for the development of anti-stimulant medications. This program of medicinal chemistry and pharmacology is intended to continue development of novel dopamine D1 partial agonists with 1) oral bioavailability and long duration of action to advance as candidate therapeutics and 2) unique pharmacological characteristics (e.g., D5 vs. D1 selectivity, 'atypical' profile of action) to serve as research tools. The pharmacology of newly synthesized compounds will be established in radioligand binding experiments, studies of adenylyl cyclase stimulation, and in vivo procedures to determine potency, duration of action, and behavioral effects in rats and primates. Lead compounds will be further studied in cocaine self-administration procedures as a preclinical test of anti-stimulant efficacy. Two major results are expected of this program. First, one or more dopamine D1 partial agonists with minimal side effects will be forwarded as candidate therapeutic(s) for the treatment of psychomotor stimulant abuse. Secondly, new research tools will be developed to study the roles of subtypes of D1- family receptors and of adenylyl cyclase in the mediation of abuse-related and other behavioral effects of stimulant drugs. PROPOSED COMMERCIAL APPLICATION: At present, there are no uniformly effective medications for the treatment of cocaine abuse and dependence, and this remains one of our most serious drug abuse problems. The development of such effective medications would have significant commercial application both for development by the pharmaceutical industry and by the government. The compounds proposed for synthesis are all novel and patentable, thus increasing their commercial value.

多巴胺D1受体参与可卡因和其他精神运动兴奋剂药物的强化和其他行为效应的证据表明，D1机制是开发抗兴奋剂药物的合理靶点。该药物化学和药理学计划旨在继续开发新型多巴胺D1部分激动剂，1)口服生物利用度和长效作用，作为候选治疗药物，2)独特的药理学特性（例如，D5与D1的选择性，“非典型”作用谱）作为研究工具。新合成化合物的药理学将在放射配体结合实验、腺苷酸环化酶刺激研究和体内程序中建立，以确定效力、作用持续时间和对大鼠和灵长类动物的行为影响。铅化合物将在可卡因自我给药过程中进一步研究，作为抗兴奋剂功效的临床前试验。预计该计划将取得两个主要成果。首先，一种或多种副作用最小的多巴胺D1部分激动剂将作为治疗精神运动兴奋剂滥用的候选治疗药物。其次，将开发新的研究工具来研究D1-家族受体亚型和腺苷酸环化酶在兴奋剂滥用相关和其他行为效应中的介导作用。拟议的商业应用：目前，没有治疗可卡因滥用和依赖的统一有效的药物，这仍然是我们最严重的药物滥用问题之一。这种有效药物的开发对于制药工业和政府的开发都具有重要的商业应用。所拟合成的化合物均具有新颖性和可申请专利性，从而提高了其商业价值。